Evidence map›Paper›PMID 15557632›Full record

ArticleInfection and immunity2004

A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential.

Robert H Copenhaver, Eliud Sepulveda, Lisa Y Armitige, Jeffrey K Actor, Audrey Wanger, Steven J Norris, Robert L Hunter, Chinnaswamy Jagannath

Abstract read
In one paragraph

Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 58 citations in OpenAlex.

  1. Construction and characterization of novelInfection and immunity · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. TheFrontiers in immunology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. The ins and outs of Mycobacterium tuberculosis protein export.Tuberculosis (Edinburgh, Scotland) · 2012
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Robert H CopenhaverDepartment of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, 6431 Fannin, Houston, TX 77030, USA.
Eliud Sepulveda
Lisa Y Armitige
Jeffrey K Actor
Audrey Wanger
Steven J Norris
Robert L Hunter
Chinnaswamy Jagannath
The University of Texas Health Science Center at Houston · US

Funding

Chracteristics of An M. Tuberculosis Derived VaccineR01AI049534 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI JAGANNATH, CHINNASWAMY · 2002 to 2011
$3.4M
NIAID NIH HHS AI 49534-01NIAID NIH HHS R01 AI049534
6 · The paper itself

Abstract

The fbpA and fbpB genes encoding the 85A and 85B proteins of Mycobacterium tuberculosis H37Rv, respectively, were disrupted, the mutants were examined for their ability to survive, and the strain lacking 85A (DeltafbpA) was tested for its ability to immunize mice. The DeltafbpA mutant was attenuated in mice after intravenous or aerosol infection, while replication of the DeltafbpB mutant was similar to that of the wild type. Complementation of the fbpA gene in DeltafbpA restored its ability to grow in the lungs of mice. The DeltafbpA mutant induced a stronger expression of pulmonary mRNA messages in mice for tumor necrosis factor alpha, interleukin-1 beta (IL-1beta), gamma interferon, IL-6, IL-2, and inducible nitric oxide (NO) synthase, which led to its decline, while H37Rv persisted despite strong immune responses. H37Rv and DeltafbpA both induced NO in macrophages and were equally susceptible to NO donors, although DeltafbpA was more susceptible in vitro to peroxynitrite and its growth was enhanced by NO inhibitors in mice and macrophages. Aerosol-infected mice, which cleared a low-dose DeltafbpA infection, resisted a challenge with virulent M. tuberculosis. Mice subcutaneously immunized with DeltafbpA or Mycobacterium bovis BCG and challenged with M. tuberculosis also showed similar levels of protection, marked by a reduction in the growth of challenged M. tuberculosis. The DeltafbpA mutant was thus attenuated, unlike DeltafbpB, but was also vaccinogenic against tuberculosis. Attenuation was incomplete, however, since DeltafbpA revived in normal mice after 370 days, suggesting that revival was due to immunosenescence but not compensation by the fbpB or fbpC gene. Antigen 85A thus affects susceptibility to peroxynitrite in M. tuberculosis and appears to be necessary for its optimal growth in mice.

Indexed as

AcyltransferasesAnimalsAntigens, BacterialCytokinesFemaleLungMaleMiceMice, Inbred C57BLMutationMycobacterium tuberculosisNitric OxideNitric Oxide SynthaseNitric Oxide Synthase Type IIPeroxynitrous AcidTuberculosis VaccinesAcyltransferasesantigen 85A, Mycobacterium tuberculosisAntigens, BacterialCytokinesNitric OxideNitric Oxide SynthaseNitric Oxide Synthase Type IINos2 protein, mousePeroxynitrous AcidTuberculosis VaccinesVaccines, Attenuated

Identifiers

PMID15557632
PMCPMC529100
OpenAlexW2110485939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.